Prot #ANV419-101: A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma

Project: Research project

Project Details

StatusActive
Effective start/end date2/9/23 → 2/9/26

Funding

  • Medpace Clinical Research LLC (Prot #ANV419-101)
  • Anaveon AG (Prot #ANV419-101)